Related Experiment Video
Updated: Jan 6, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
HMGB1 and Its Signaling Pathway in Osteosarcoma: Current Advances in Targeted Therapy
Zhuosheng Liu1, Fucai Wang1, Zhihan Zhou1
1School of Medicine, Huaqiao University, Quanzhou 362021, China.
Abstract:
This article reviews the research progress for high-mobility group protein B1 (HMGB1) and its signaling pathway in osteosarcoma (OS) and discusses its application potential in targeted therapy. A large number of domestic and foreign studies were reviewed to summarize the research results on the the biological function, signal pathway regulation mechanism, and intervention strategy of HMGB1 in recent years. HMGB1 promotes OS cell proliferation, invasion, and immune escape by activating RAGE, TLR4, and downstream MAPK, NF-κB, and PI3K/AKT signaling pathways. Interfering with HMGB1 or its signaling axis shows good antitumor potential in in vitro and in vivo models, but clinical transformation is still limited by its dual biological effects and tumor heterogeneity. HMGB1 and its related signaling pathways are important targets for the treatment of osteosarcoma. In the future, the development of a multi-channel combined intervention and efficient delivery system will provide a new direction for improving the therapeutic effect.
Insights
High-mobility group protein B1 (HMGB1) fuels osteosarcoma growth and immune evasion. Targeting HMGB1 and its pathways shows promise for osteosarcoma treatment, though clinical use faces challenges.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- High-mobility group protein B1 (HMGB1) is implicated in various cancers.
- Its role in osteosarcoma (OS) pathogenesis and therapeutic potential requires comprehensive review.
Purpose of the Study:
- To review current research on HMGB1 and its signaling pathways in osteosarcoma.
- To discuss the therapeutic application potential of targeting HMGB1 in OS.
Main Methods:
- Systematic review of domestic and international studies on HMGB1 in osteosarcoma.
- Analysis of HMGB1's biological functions, signaling pathways, and intervention strategies.
Main Results:
- HMGB1 promotes OS cell proliferation, invasion, and immune escape via RAGE, TLR4, MAPK, NF-κB, and PI3K/AKT pathways.
- Interference with HMGB1 or its signaling axis demonstrates antitumor potential in preclinical models.
- Clinical translation is hindered by HMGB1's dual effects and OS tumor heterogeneity.
Conclusions:
- HMGB1 and its signaling pathways represent crucial therapeutic targets for osteosarcoma.
- Future strategies may involve multi-channel interventions and advanced delivery systems for improved efficacy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Hedgehog Signaling Pathway

